Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 22, 2004
ATLAS is the first clinical trial using Boston Scientific's new Liberté coronary stent as a platform for its paclitaxel-eluting coronary stent system.
-
Jul 21, 2004
A live webcast and replay of the July 26 conference call will be available.
-
Jul 16, 2004
"Patient safety continues to be our highest priority," said Jim Tobin, President and Chief Executive Officer.
-
Jul 8, 2004
Prospective, multi-center, randomized study designed to evaluate the benefits of filter-based embolic protection during primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI).
-
Jul 2, 2004
The voluntary recall does not affect patients who have already received a TAXUS stent.
-
Jun 25, 2004
Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.
-
Jun 22, 2004
Company announces launch of a public offering of $500 million aggregate principal amount of senior notes.
-
Jun 8, 2004
A live webcast and replay of the June 9th conference session will be available.
-
Jun 3, 2004
Company estimates that its share of the U.S. drug-eluting stent market - as of May 31st - continues to be in excess of 70 percent, on a reorder basis.
-
Jun 1, 2004
Acquisition will bring neuromodulation technology, including a range of neurostimulators, programmable drug pumps and cochlear implants.
-
May 28, 2004
(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...
-
May 26, 2004
Trial assessed the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics.
-
May 25, 2004
Company made the announcement at the annual Paris Course on Revascularization, the largest interventional cardiology conference in Europe.
-
May 24, 2004
Company expects to announce 30-day results at the 2004 Transcatheter Cardiovascular Therapeutics conference in September.
-
May 20, 2004
A replay of the May 26 analyst meeting will also be available. Learn how to tune into the webcast.
-
May 20, 2004
Enteryx found equally effective in controlling GERD symptoms in patients previously treated with proton pump inhibitor (PPI) medications at both standard and high dosing.
-
May 18, 2004
Company made the announcement at the annual Digestive Disease Week (DDW) conference.
-
May 17, 2004
A live webcast and replay of the May 19 conference session will be available.
-
May 4, 2004
"The TAXUS launch continues to go extremely well, with sales growing and execution remaining strong," said Jim Tobin, President and Chief Executive Officer.
-
May 1, 2004
Company estimates that its share of the U.S. drug-eluting stent market - as of May 14 - continues to be in excess of 70 percent, on a reorder basis.
-
Apr 30, 2004
A live webcast and replay of the May 6 conference session will be available. Read more.
-
Apr 20, 2004
"This quarter saw the achievement of a major milestone for Boston Scientific with the successful launch of TAXUS in the U.S.," said Jim Tobin, President and CEO.
-
Apr 19, 2004
Combines features from two of Boston Scientific's breakthrough technologies.
-
Apr 14, 2004
Boston Scientific will webcast its conference call with Q1 2004 financial results on Tuesday, April 20. A replay will also be available.
-
Apr 8, 2004
FDA clearance expands Company's family of high-performance self-expanding biliary stents